2,500 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by Anthracite Investment Company Inc.

Anthracite Investment Company Inc. purchased a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,500 shares of the company's stock, valued at approximately $2,215,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC increased its stake in shares of Eli Lilly and Company by 87,091.7% in the 3rd quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company's stock worth $11,041,631,000 after acquiring an additional 12,448,888 shares during the last quarter. Capital Research Global Investors increased its holdings in Eli Lilly and Company by 6.0% during the 1st quarter. Capital Research Global Investors now owns 8,031,531 shares of the company's stock worth $6,248,210,000 after purchasing an additional 453,939 shares during the period. Capital International Investors lifted its position in shares of Eli Lilly and Company by 5.1% during the 1st quarter. Capital International Investors now owns 6,972,393 shares of the company's stock worth $5,424,243,000 after purchasing an additional 335,560 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Eli Lilly and Company by 5.0% during the second quarter. Dimensional Fund Advisors LP now owns 3,581,075 shares of the company's stock worth $3,242,296,000 after purchasing an additional 171,595 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in Eli Lilly and Company by 7.3% during the 1st quarter. Janus Henderson Group PLC now owns 3,575,684 shares of the company's stock worth $2,781,613,000 after acquiring an additional 243,729 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company's stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Up 3.2 %

Shares of NYSE:LLY traded up $23.68 during midday trading on Wednesday, hitting $753.41. The stock had a trading volume of 5,116,185 shares, compared to its average volume of 3,185,802. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The business's 50-day simple moving average is $875.60 and its 200-day simple moving average is $870.81. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market cap of $715.23 billion, a P/E ratio of 80.40, a PEG ratio of 2.82 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company's revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 earnings per share. On average, sell-side analysts forecast that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 56.22%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on LLY. Cantor Fitzgerald reissued an "overweight" rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an "overweight" rating in a report on Friday, August 9th. Barclays decreased their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating for the company in a report on Thursday, October 31st. Bank of America reduced their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a "buy" rating for the company in a research note on Thursday, October 31st. Finally, Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a "buy" rating in a report on Wednesday, August 14th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average target price of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.